newsBristol-Myers Squibb shares significant new findings in rheumatoid arthritis research8 June 2016 | By Mandy Parrett, Editorial AssistantGlobal biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
newsBMS and MD Anderson in lung cancer research collaboration7 June 2016 | By Victoria White, Digital Content ProducerBMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients...
newsBMS presents new data for Opdivo at ASCO6 June 2016 | By Victoria White, Digital Content ProducerNew data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
newsData support Opdivo as new standard of care in mRCC, says GlobalData1 June 2016 | By Victoria White, Digital Content ProducerNew data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
newsEC approves Empliciti as combination therapy for multiple myeloma12 May 2016 | By Victoria White, Digital Content ProducerEmpliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
newsNICE says ‘no’ to Opdivo for non-squamous NSCLC12 May 2016 | By Victoria White, Digital Content ProducerIn draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...
newsEC approves Opdivo + Yervoy regimen for advanced melanoma11 May 2016 | By Victoria White, Digital Content ProducerThe approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
newsCoulter Partners secures further nomination to Curetis N.V. Supervisory Board10 May 2016 | By Coulter PartnersCoulter Partners was delighted to partner once again with German / Dutch diagnostics company Curetis N.V...
news3rd Pharmaceutical Traceability Forum to attract expert serialization and packaging professionals from across the nation29 April 2016 | By 3rd Pharmaceutical Traceability ForumHarmonize serialization plans to achieve compliance. Supply chain stakeholders must take a comprehensive view of their traceability strategy...
newsFDA grants Breakthrough Therapy Designation to Opdivo in SCCHN25 April 2016 | By Victoria White, Digital Content ProducerThe designation is based on results of a Phase III trial evaluating Opdivo versus investigator’s choice of therapy in patients with SCCHN...
newsOpdivo and Yervoy combination demonstrates superior efficacy in melanoma study18 April 2016 | By Victoria White, Digital Content ProducerA Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
newsFDA accepts sBLA for Opdivo in classical Hodgkin Lymphoma15 April 2016 | By Victoria White, Digital Content ProducerThe FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies...
newsEC approves Opdivo in NSCLC and advanced kidney cancer14 April 2016 | By Victoria White, Digital Content ProducerThe EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
newsEC expands use of Opdivo in NSCLC and approves its use in advanced RCC6 April 2016 | By Victoria WhiteThe EC has approved Opdivo (nivolumab) for locally advanced or metastatic NSCLC after prior chemotherapy and in advanced RCC after prior therapy...
newsPeter J. Arduini elected to the board of Bristol-Myers Squibb4 March 2016 | By Victoria WhiteMr. Arduini is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company...
